Teva's Arie Belldegrun resigns
On January 26, 2017, Dr Arie Belldegrun resigned as a member of the board of directors of Teva Pharmaceutical Industries (NYSE: TEVA), according to a company regulatory filing.
In his resignation, Dr Belldegrun stated his need to focus on his responsibilities as chairman, president, chief executive and founder of Kite Pharma (Nasdaq: KITE), as the company enters a critical juncture in its growth with important milestones anticipated in 2017.
Dr Belldegrun joined Teva’s board of directors in 2013 and would have stood for election at the 2019 annual meeting. The company thanks Dr Belldegrun for his years of dedicated service and wishes him well in his other endeavors, said Teva.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze